ArticleBMC bioinformatics2013
Genome-wide prediction of vaccine targets for human herpes simplex viruses using Vaxign reverse vaccinology.
Article in BMC bioinformatics, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
35 citing papers in PubMed, 1 synthesis or guideline pooled it, 79 citations in OpenAlex.
- COVID-19 Coronavirus Vaccine Design Using Reverse Vaccinology and Machine Learning.Frontiers in immunology · 2020Pooled it
- Pangenomics-Driven Reverse Vaccinology for the Discovery of New Vaccine Candidates AgainstBioinformatics and biology insights · 2026Article
- Genomic Scale Analysis Foresees Enteroprotective and Butyrogenic Properties in Brazilian Isolates of Lactiplantibacillus plantarum.Probiotics and antimicrobial proteins · 2025Article
- Article
- Article
- Integrating pan-genome and reverse vaccinology to design multi-epitope vaccine against Herpes simplex virus type-1.3 Biotech · 2024Article
- Design of multi-epitope vaccine candidate against Brucella type IV secretion system (T4SS).PloS one · 2023Article
- Immunopeptidomics-based design of mRNA vaccine formulations against Listeria monocytogenes.Nature communications · 2022Article
- Proteome Exploration ofMicrobiology spectrum · 2022Article
- Design of a multi-epitope vaccine candidate against Brucella melitensis.Scientific reports · 2022Article
- Comparative Reverse Vaccinology ofVaccines · 2022Article
- Application of Reverse Vaccinology and Immunoinformatic Strategies for the Identification of Vaccine Candidates Against Shigella flexneri.Methods in molecular biology (Clifton, N.J.) · 2022Article
- Artificial Intelligence-Based Data-Driven Strategy to Accelerate Research, Development, and Clinical Trials of COVID Vaccine.BioMed research international · 2022Review
- Identification of anti-horn fly vaccine antigen candidates using a reverse vaccinology approach.Parasites & vectors · 2021Article
- Reverse Microbiomics: A New Reverse Dysbiosis Analysis Strategy and Its Usage in Prediction of Autoantigens and Virulent Factors in Dysbiotic Gut Microbiomes From Rheumatoid Arthritis Patients.Frontiers in microbiology · 2021Article
- Molecular tools-advances, opportunities and prospects for the control of parasites of veterinary importance.International journal of tropical insect science · 2021Review
- COVID-19 coronavirus vaccine design using reverse vaccinology and machine learning.bioRxiv : the preprint server for biology · 2020Article
- Immunoinformatics and Vaccine Development: An Overview.ImmunoTargets and therapy · 2020Review
- Delineation of the pan-proteome of fish-pathogenic Streptococcus agalactiae strains using a label-free shotgun approach.BMC genomics · 2019Article
- Identification of Streptococcus mitis321A vaccine antigens based on reverse vaccinology.Molecular medicine reports · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Herpes simplex virus (HSV) types 1 and 2 (HSV-1 and HSV-2) are the most common infectious agents of humans. No safe and effective HSV vaccines have been licensed. Reverse vaccinology is an emerging and revolutionary vaccine development strategy that starts with the prediction of vaccine targets by informatics analysis of genome sequences. Vaxign (http://www.violinet.org/vaxign) is the first web-based vaccine design program based on reverse vaccinology. In this study, we used Vaxign to analyze 52 herpesvirus genomes, including 3 HSV-1 genomes, one HSV-2 genome, 8 other human herpesvirus genomes, and 40 non-human herpesvirus genomes. The HSV-1 strain 17 genome that contains 77 proteins was used as the seed genome. These 77 proteins are conserved in two other HSV-1 strains (strain F and strain H129). Two envelope glycoproteins gJ and gG do not have orthologs in HSV-2 or 8 other human herpesviruses. Seven HSV-1 proteins (including gJ and gG) do not have orthologs in all 40 non-human herpesviruses. Nineteen proteins are conserved in all human herpesviruses, including capsid scaffold protein UL26.5 (NP_044628.1). As the only HSV-1 protein predicted to be an adhesin, UL26.5 is a promising vaccine target. The MHC Class I and II epitopes were predicted by the Vaxign Vaxitop prediction program and IEDB prediction programs recently installed and incorporated in Vaxign. Our comparative analysis found that the two programs identified largely the same top epitopes but also some positive results predicted from one program might not be positive from another program. Overall, our Vaxign computational prediction provides many promising candidates for rational HSV vaccine development. The method is generic and can also be used to predict other viral vaccine targets.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.